On Friday a three‑judge panel of the Fifth Circuit issued a temporary stay that blocks abortion providers from prescribing mifepristone via telemedicine and mailing the pills to patients. The order responds to a lawsuit filed by Louisiana, which argues that mail‑order distribution circumvents the state’s near‑total abortion ban. Providers must now revert to in‑person dispensing nationwide.

Federal regulators had lifted a long‑standing in‑person requirement for the drug in 2023, expanding access that clinics and telehealth firms quickly monetized. Industry analysts estimate the mail‑order channel accounts for roughly a third of U.S. mifepristone sales, translating into tens of millions of dollars in revenue. The stay therefore threatens a sizable profit stream and could prompt refund litigation.

Earlier this spring a district court in New Orleans declined to freeze the policy, directing parties to wait for the FDA’s pending safety review, slated for late 2026. By granting Louisiana’s emergency request, the appellate court creates immediate operational uncertainty for pharmacies, insurance carriers and telehealth platforms that have built logistics around home delivery. The ruling underscores how state litigation can reshape a multibillion‑dollar pharmaceutical market.